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Abstract
Introduction: Microvasculopathy is one of the characteristic features in patients with systemic sclerosis (SSc), but
underlying mechanisms still remain uncertain. In this study, we evaluated the potential involvement of monocytic
endothelial progenitor cells (EPCs) in pathogenic processes of SSc vasculopathy, by determining their number and
contribution to blood vessel formation through angiogenesis and vasculogenesis.
Methods: Monocytic EPCs were enriched and enumerated using a culture of peripheral blood mononuclear cells
and platelets on fibronectin in 23 patients with SSc, 22 patients with rheumatoid arthritis (RA), and 21 healthy
controls. To assess the capacity of monocytic EPCs to promote vascular formation and the contribution of
vasculogenesis to this process, we used an in vitro co-culture system with human umbilical vein endothelial cells
(HUVECs) on Matrigel® and an in vivo murine tumor neovascularization model.
Results: Monocytic EPCs were significantly increased in SSc patients than in RA patients or healthy controls (P = 0.01
for both comparisons). Monocytic EPCs derived from SSc patients promoted tubular formation in Matrigel® cultures
more than those from healthy controls (P = 0.007). Transplantation of monocytic EPCs into immunodeficient mice
resulted in promotion of tumor growth and blood vessel formation, and these properties were more prominent in
SSc than healthy monocytic EPCs (P = 0.03 for both comparisons). In contrast, incorporation of SSc monocytic EPCs
into the tubular structure was less efficient in vitro and in vivo, compared with healthy monocytic EPCs.
Conclusions: SSc patients have high numbers of aberrant circulating monocytic EPCs that exert enhanced
angiogenesis but are impaired in vasculogenesis. However, these cells apparently cannot overcome the anti-
angiogenic environment that characterizes SSc-affected tissues.
Introduction
Systemic sclerosis (SSc) is a multi-system connective tis-
sue disease characterized by excessive fibrosis and
microvascular abnormalities. SSc vasculopathy mainly
affects small arteries, causing reduced blood flow and
tissue ischemia, which leads to Raynaud’sp h e n o m e n o n ,
digital ulcers, and gangrene [1]. The pathogenesis of SSc
vasculopathy is not fully understood, but several lines of
evidence have shown that the primary mechanism
involves enhanced vascular injury, occurring as a result
of an inflammatory-immune response and ischemia-
reperfusion reactions [2,3]. On the other hand, defective
vascular repair machinery has recently been proposed as
an alternative mechanism [4].
The formation and repair of blood vessels in adults are
mediated through two different processes: angiogenesis is
a process of sprouting from pre-existing vessels; it
involves the proliferation and migration of mature
endothelial cells. Vasculogenesis is mediated through the
recruitment and in situ differentiation of bone marrow-
derived endothelial progenitor cells (EPCs) [5]. Human
EPCs, also termed circulating endothelial precursors, are
progenitors lacking typical hematopoietic markers that
give rise to endothelium and are characterized by a
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lar endothelial growth factor (VEGF) receptor type 2 [6].
We recently reported defective vasculogenesis in SSc
patients, based on the reduced number of EPCs in circu-
lation and their impaired maturation potential [7]. How-
ever, whether the number of EPCs in SSc patients is
reduced or not is a matter of debate [8].
A subpopulation of circulating CD14
+ monocytes also
has EPC-like characteristics, in terms of their expression
of endothelial markers upon endothelial induction, for-
mation of tube-like structures in vitro, and incorpora-
tion into newly formed blood vessels in vivo [9]. This
EPC subset of myeloid origin, termed monocytic EPCs,
is apparently distinct from “classic” EPCs [10] and may
share characteristics of early outgrowth cells and circu-
lating angiogenic cells [11]. Monocytic EPCs are now
considered oligopotent cells that may differentiate into
endothelium as well as into other elements of the vascu-
lature, such as pericytes and smooth muscle cells, but
their in vivo vasculogenic potential is far inferior to
“classic” EPCs [12]. In addition, monocytic EPCs contri-
bute to new vessel formation and vascular repair
through angiogenesis by angiogenic factor secretion and
other mechanisms [11,12].
We recently reported that primitive cells with the
capacity to differentiate into various types of mesenchy-
mal-lineage cells and into endothelial cells can be
enriched from a subpopulation of circulating monocytes
in an in vitro culture system [13-15]. These cultured
cells, termed monocyte-derived multipotential cells,
have a spindle-shaped morphology and a unique pheno-
type positive for CD14, CD45, CD34, and type I collagen
[13]. Since these monocyte-derived cells are capable of
proliferating and differentiating along the endothelial
lineage in vitro and in vivo [15], it is reasonable to say
that circulating precursors for monocyte-derived multi-
potential cells are compatible with or belong among the
monocytic EPCs. In this study, we evaluated the poten-
tial involvement of monocytic EPCs in SSc vasculopathy
by examining their quantity as well as their angiogenic
and vasculogenic properties using the procedure to
enrich circulating precursors for monocyte-derived mul-
tipotential cells.
Materials and methods
Patients and controls
We studied blood samples from 23 patients with SSc,
5 men and 18 women (60.2 ± 14.8 years), who fulfilled
the American College of Rheumatology (ACR) prelimin-
ary classification criteria [16], and from 21 healthy con-
trols, 4 men and 17 women (63.6 ± 10.4 years). In some
analyses, samples from 22 patients with rheumatoid
arthritis (RA), 2 men and 20 women (58.8 ± 8.1 years),
who fulfilled the ACR classification criteria [17], were
used as a disease control. Eighteen SSc patients (78%)
were classified as having diffuse cutaneous SSc according
to published criteria [18]. Disease duration was 11.1 ± 9.6
years, and 10 (43%) patients had received their diagnosis
within five years. Clinical characteristics at the time of
blood sampling are summarized in Table 1. A series of
SSc-related autoantibodies were determined using indir-
ect immunofluorescence and immunoprecipitation assays
[19]. None of SSc patients received cytotoxic drug at any-
time in their illness, but six patients were on low-dose
corticosteroids (< 10 mg/day) at examination. All samples
were obtained after the patients and control subjects gave
their written informed consent in accordance with the
tenets of the Declaration of Helsinki, as approved by the
International Review Boards of Keio University and
Yokohama City University.
Preparation and quantification of monocytic EPCs
Monocytic EPCs were enriched using a culture system we
developed previously [13] with some modifications. Briefly,
peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized peripheral blood by Lymphoprep (Frese-
nius Kabi Norge AS, Halden, Norway) density-gradient
centrifugation. Since the number of platelets and micro-
particles contaminating the PBMC fraction influences
the recovery of monocytic EPCs in cultures [20],
PBMCs were first subjected to platelet depletion with the
MACS® system (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) using anti-CD61 monoclonal antibody (mAb)-
coupled magnetic beads. Platelet-depleted PBMCs (3 ×
10
6) were then cultured in duplicate on fibronectin-coated
six-well plates with autologous platelets (3 × 10
7) in low-
glucose Dulbecco’s modified Eagle’s medium supplemen-
ted with 10% fetal bovine serum (JRH Bioscience, Lenexa,
KS, USA), 2 mM L-glutamine, 50 U/ml penicillin, and 50
mg/ml streptomycin (without any additional growth
Table 1 Clinical characteristics at the time of blood
sampling in 23 patients with SSc*
Raynaud’s phenomenon 23 (100%)
Digital ulcers 9 (39%)
Interstitial lung disease 10 (43%)
Current smoker 1 (4%)
Past smoker 1 (4%)
Hypertension 6 (26%)
Hypercholesterolemia 4 (17%)
Positive anti-nuclear antibody 23 (100%)
Positive anticentromere 8 (35%)
Positive anti-topoisomerase I 5 (22%)
Positive anti-U1RNP 2 (9%)
Positive anti-Th/To 3 (13%)
Positive anti-RNA polymerase III 2 (9%)
* The results are expressed as the number and frequency (%).
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medium, which contained floating cells, was exchanged
for fresh medium at Day 3. At 10 days of culture, adherent
cells with a spindle-like morphology were counted under
an inverted microscope. The number of monocytic EPCs
in 1 mL of peripheral blood was calculated as the mean of
multiple measurements in proportion to the volume of
peripheral blood that yielded 3 × 10
6 PBMCs at the isola-
tion procedure. The expression of CD1a, CD14 CD34,
CD80, CD83, and VEGF receptor type 1 (VEGFR1) and
uptake of 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbo-
cyanine (Dil)-labeled acetylated low-density lipoprotein
(acLDL) (2.5 mg/ml: Molecular Probes, Eugene, OR, USA)
in monocytic EPCs was evaluated by flow cytometry, while
expression of CD31, CD144, and VEGFR1 on adherent
cells was evaluated by immunohistochemistry [13].
In some instances, monocytic EPCs were cultured on
fibronectin-coated plastic plates for 3, 5, 7, 10, and 14
days in endothelial cell basal medium-2 (EBM-2; Clo-
netics, San Diego, CA, USA) supplemented with EBM-2
MV SingleQuots® (Clonetics) containing 5% fetal bovine
serum, VEGF, basic fibroblast growth factor, epidermal
growth factor, insulin-like growth factor-1, heparin, and
ascorbic acid [15]. The medium was exchanged with
fresh medium every three to four days. Differentiation
into mature endothelial cells was evaluated by immuno-
histochemistry for expression of VEGF receptor type 2
(VEGFR2) and von Willebrand factor (vWF) [15].
In vitro vascular tube formation in Matrigel® culture
The capacity of monocytic EPCs to promote the forma-
tion of tubular structures by mature endothelial cells
was examined in Matrigel® culture (BD Biosciences, San
Diego, CA, USA) as described previously [15]. Briefly, a
suboptimal number (10
4) of human umbilical vein
endothelial cells (HUVECs), which formed a small num-
ber of short tubular structures when cultured alone,
were cultured in duplicate in EBM-2 supplemented with
EBM-2 MV SingleQuots® on 12-well Matrigel® plates
(BD Biosciences) with or without monocytic EPCs (10
4).
Each experiment was conducted by pairing samples of
monocytic EPCs derived from SSc patients and from
healthy controls. As a control, monocytic EPCs were
cultured alone on Matrigel®.A f t e r2 4h o u r s ,t h et o t a l
tube length in each well was measured. The capacity of
monocytic EPCs to enhance tubular formation was
assessed as the ratio of the total tube length in the cul-
ture of HUVECs plus monocytic EPCs to the length in
the culture of HUVECs alone. In some instances, culture
supernatants of HUVECs (10
4) plus monocytic EPCs
(10
4) in EBM-2 supplemented with EBM-2 MV Single-
Quots® on 12-well Matrigel® plates were collected as
conditioned medium, and used in the second Matrigel®
cultures with HUVECs alone (10
4). The capacity to
enhance tubular formation was assessed as the ratio of
the total tube length in the culture with conditioned
medium of HUVECs plus monocytic EPCs to the length
in the culture with conditioned medium of HUVECs
alone.
In some experiments, monocytic EPCs and HUVECs
were pre-labeled with PKH67 (Sigma, St. Louis, MO,
USA), and Dil-acLDL, respectively, and cultured together
in Matrigel® [15]. The cells were observed at 24 hours
under a fluorescence microscope, and the capacity of the
monocytic EPCs to be incorporated into the tubular
structure was evaluated as the number of PKH67-labeled
monocytic EPC-derived cells within the tubular structure
divided by the total tube length (cells/mm).
In vivo tumor neovascularization model
A murine tumor neovascularization model was described
previously [15]. Briefly, murine colon carcinoma CT-26
cell line cells (2.5 × 10
5) were transplanted beneath the
skin of the back of severe combined immunodeficient
(SCID) mice (Charles River Japan, Yokohama, Japan) in
conjunction with or without monocytic EPCs (10
4 or
10
5). Each experiment was conducted using a pair of
monocytic EPCs derived from SSc patients and from
healthy controls. Ten days later, the mice were sacrificed
and the volume of the subcutaneous tumor was calcu-
lated as follows: 0.5 × longest diameter × (shortest dia-
meter)
2. Formalin-fixed, paraffin-embedded specimens
were stained with hematoxylin and eosin. The number of
blood vessels carrying erythrocytes was counted in 10
independent fields at a magnification of x10, and the
results were expressed as the mean. Frozen specimens
(8-mm thick) were incubated with rat anti-mouse CD31
mAb (BD Biosciences) in combination with mouse anti-
human CD31 mAb-fluorescein isothiocyanate (FITC)
conjugate (Chemicon, Temecula, CA, USA) or mouse
anti-human leukocyte antigen (HLA) class I-FITC conju-
gate (Sigma), followed by incubation with Alexa-
Fluor®488 anti-FITC and AlexaFluor®568 anti-rat-
specific IgG antibodies (Molecular Probes). Negative con-
trols were sections incubated with isotype-matched
mouse or rat mAb to an irrelevant antigen, instead of the
primary antibody. Nuclei were counter-stained with TO-
PRO3 (Molecular Probes). These slides were examined
with a confocal laser fluorescence microscope (LSM5
PASCAL; Carl-Zeiss, Göttingen, Germany). The effi-
ciency of monocytic EPC incorporation into the vascular
wall was evaluated as the proportion of blood vessels
containing human CD31-expressing endothelial cells in
at least 100 blood vessel sections.
Statistical analysis
All continuous variables were expressed as the mean ±
standard deviation. Comparisons between two groups
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Whitney U test or Wilcoxon t-test as appropriate.
Results
Number of monocytic EPCs
We enriched for monocytic EPCs by culturing PBMCs
on fibronectin with autologous platelets. After 10 days,
adherent cells with a spindle-shaped morphology made
their appearance in all cultures (Figure 1a). Nearly all
adherent cells obtained in this culture were positive for
both CD14 and CD34 (Figure 2a), as shown in our
previous report [13]. These adherent cells expressed
VEGFR1 and incorporated Dil-labeled acLDL, but lacked
expression for dendritic cell markers CD1a and CD83 or
a mature macrophage marker CD80 (Figure 2a). Immu-
nohistochemistry showed expression of a series of
endothelial markers, including CD31, CD144, and
VEGFR1, by nearly all adherent cells (Figure 2b). These
findings indicate that monocytic EPCs enriched in our
culture system with fibronectin are a homogeneous cell
population in terms of protein expression profiles.
When the number of monocytic EPCs was compared
among 23 patients with SSc, 22 with RA, and 21 healthy
controls, there were significantly more monocytic EPCs
in cultures derived from SSc patient samples, than in
those from RA patients or healthy controls (P = 0.01 for
both comparisons; Figure 1b). There was no significant
association between the number of monocytic EPCs in
culture and the SSc patients’ disease duration, disease
subset, digital ulcers, interstitial lung disease, SSc-related
autoantibodies, or treatment with corticosteroids.
Capacity of monocytic EPCs to promote tubule formation
in vitro
We first evaluated potentials of monocytic EPCs to dif-
ferentiate into mature endothelial cells in vitro. Monocy-
tic EPCs from seven patients with SSc and seven healthy
controls cultured in endothelial induction medium
resulted in expression of mature endothelial cell markers
VEGFR2 and vWF, and expression of VEGFR2 and vWF
was observed after Days 5 and 7, respectively, in all
samples irrespective of the presence or absence of SSc
(data not shown).
Next, monocytic EPCs from healthy and SSc subjects
cultured alone on Matrigel® failed to form tubular struc-
tures, but they promoted tubule formation in 24-hour
co-culture with HUVECs (Figure 3a). In this short-term
culture, tube was formed mainly by cell migration.
When we examined monocytic EPCs derived from 15
pairs of SSc patients and healthy controls (Figure 3b),
Figure 1 Monocytic EPCs enriched in culture on fibronectin. (a) Representative images of monocytic EPCs cultured for 10 days, from an SSc
patient, an RA patient, and a healthy control. Adherent cells with a typical spindle shape are regarded as monocytic EPCs. Scale bars = 500 mm.
(b) Monocytic EPCs were quantified in SSc patients, RA patients, and healthy controls, and expressed as the number in 1 mL of peripheral blood.
Horizontal bars indicate the mean values. NS, not significant.
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structure formation was significantly greater in cultures
from SSc patients than in those from healthy controls
(P = 0.0007).
Two potential mechanisms could account for the
monocytic EPCs’ role in promoting tubule formation
in vitro: the support of tubule formation by HUVECs
and their own incorporation into the tubular structure.
To examine whether the former mechanism was
involved in this process, we collected supernatants of
the Matrigel® cultures as conditioned medium, and
examined their capacity to promote tube formation
in the second Matrigel® cultures with HUVECs alone
(Figure 4). The conditioned medium was prepared from
the first cultures with HUVECs plus monocytic EPCs
(10
4) derived from seven pairs of SSc patients and
healthy controls, and from the cultures with HUVECs
alone. The capacity to enhance tubular formation was
significantly greater in SSc-derived conditioned medium
than in healthy control-derived medium (P = 0.04).
To further evaluate the ability of monocytoc EPCs to
be incorporated into the tubular structures, monocytic
EPCs were pre-labeled with a green fluorescent cell lin-
ker PKH67 and cultured with Dil-acLDL-labeled
HUVECs in Matrigel®. We found that a small number
of monocytic EPCs were integrated into tubular struc-
tures that were primarily formed by HUVECs (Figure
5a). When we tested monocytic EPCs derived from 10
pairs of SSc patients and healthy controls (Figure 5b),
their capacity to integrate into tubule formation was less
efficient in the SSc-derived cultures than in those from
healthy controls (P = 0.01).
Capacity of monocytic EPCs to promote
neovascularization in vivo
The in vivo capacity of monocytic EPCs to promote
blood vessel formation was evaluated using a murine
tumor neovascularization model [15]. Murine colon car-
cinoma CT-26 cells were injected beneath the back of
SCID mice, either alone or in combination with mono-
cytic EPCs derived from SSc patients or healthy con-
trols. As shown in Figure 6, co-transplantation of CT-26
cells with monocytic EPCs promoted tumor growth, and
the amount of growth depended on the number of
Figure 2 Protein expression profiles of monocytic EPCs. (a) Flow cytometric analysis of monocytic EPCs derived from a healthy control. Cells
were stained with anti-CD14 mAb plus mAb to CD34, VEGFR1, CD1a, CD83, or CD80, and analyzed by flow cytometry. (b) Immunohistochemical
analysis of monocytic EPCs. Cells were stained with a mouse mAb to the endothelial marker, as indicated. Controls were incubated with an
isotype-matched mouse mAb to an irrelevant antigen. Nuclei were counterstained with hematoxylin. Bars, 50 μm.
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from the co-transplantation of monocytic EPCs from
SSc patients or healthy controls showed that the SSc-
derived monocytic EPCs promoted significantly faster
tumor growth (P = 0.03).
A histological examination of the tumors showed that
the co-transplantation of monocytic EPCs dramatically
increased the number of blood vessels carrying erythro-
cytes compared with the transplantation of CT-26 cells
alone, especially when SSc-derived monocytic EPCs
were used (Figure 7a). Consecutive sections of the
tumors co-transplanted with SSc-derived monocytic
EPCs confirmed lateral connection of blood vessels
detected as a longitudinal vessel section in the single
s e c t i o n( F i g u r e7 b ) .A ss h o w ni nF i g u r e7 c ,t h en u m b e r
of blood vessels in the tumor tissue increased with the
number of transplanted monocytic EPCs, and was signif-
icantly greater in tumors that arose from the transplan-
tation of CT-26 cells with SSc-derived monocytic EPCs
than with control monocytic EPCs (P = 0.03 for the
transplantation of 10
4 and 10
5 monocytic EPCs). Thus,
Figure 3 Capacity of monocytic EPCs to promote tubular
formations in co-culture with HUVECs in Matrigel
®. (a)
Representative images of Matrigel
® cultures of HUVECs (10
4) alone,
monocytic EPCs (10
4) from an SSc patient alone, and HUVECs (10
4)
plus monocytic EPCs (10
4) from an SSc patient and a healthy control.
Scale bars = 1 mm. (b) Capacity of monocytic EPCs to enhance the
tubular formation was expressed as the ratio of total tube length in
the culture of HUVECs plus monocytic EPCs to the length in the
culture of HUVECs alone, and compared between SSc patients and
healthy controls. Horizontal bars indicate the mean values.
Figure 4 Capacity of monocytic EPC-derived conditioned
medium to promote tubular formations in culture of HUVECs
in Matrigel
®. (a) Representative images of Matrigel
® cultures of
HUVECs in the presence of culture supernatants of HUVECs (10
4)
alone, HUVECs (10
4) plus monocytic EPCs (10
4) from an SSc patient,
and HUVECs (10
4) plus monocytic EPCs (10
4) from a healthy control.
Scale bars = 500 μm. (b) Capacity to enhance tubular formation
was expressed as the ratio of total tube length in the culture with
conditioned medium of HUVECs plus monocytic EPCs to the length
in the culture with conditioned medium of HUVECs alone, and
compared between SSc patients and healthy controls. Horizontal
bars indicate the mean values.
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SSc-derived monocytic EPCs could be explained by the
EPCs’ enhanced ability to promote blood vessel forma-
tion in vivo.
To further examine the contribution of vasculogenesis
in this process, we evaluated the distribution of the
transplanted human monocytic EPCs in the tumors by
detecting cells expressing human CD31 (Figure 8a). The
majority of transplanted monocytic EPCs expressing
human CD31 were detected outside of the vascular
lumen, but some blood vessels included cells expressing
human CD31 but did not express mouse CD31 (Figure
8b). Similar findings were observed when mAb to HLA
class I was used instead of anti-human CD31 mAb.
When the proportion of blood vessels carrying endothe-
lial cells expressing human CD31 was evaluated, fewer
monocytic EPCs from SSc patients were incorporated
into the vascular wall than monocytic EPCs from healthy
Figure 5 In vitro vasculogenic property of monocytic EPCs in
Matrigel
® culture. Monocytic EPCs labeled with PKH67 (green) and
HUVECs labeled with Dil-acetylated LDL (red) were cultured
together on Matrigel
®. (a) Typical phase-contrast (left) and
fluorescent (right) images of the same field of monocytic EPCs from
an SSc patient (upper) and a healthy control (lower). An arrow
indicates a monocytic EPC-derived cell incorporated into the tubular
structure. Scale bars = 100 μm. (b) The vasculogenic property of
monocytic EPCs was calculated as the number of monocytic EPCs
within the tubular structure divided by the total tube length (cells/
mm), and compared between SSc patients and healthy controls.
Horizontal bars indicate the mean values.
Figure 6 Tumor growth after transplantation of monocytic
EPCs in the in vivo tumor neovascularization model. Tumors
from colon carcinoma CT-26 cells injected subcutaneously into the
back of mice alone or in combination with monocytic EPCs (10
4 or
10
5) derived from SSc patients or healthy controls. Tumor growth
was assessed 10 days later. (a) Representative subcutaneous tumors
from mice that received transplanted CT-26 cells alone, or CT-26
cells along with monocytic EPCs (10
4 or 10
5) from a healthy control
or an SSc patient. (b) Tumor volumes in mice that received
transplants of CT-26 cells alone, or CT-26 cells in combination with
monocytic EPCs from SSc patients or healthy controls (10
4 or 10
5).
Results are shown as the mean and standard deviation.
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10
4 and 10
5 monocytic EPCs were used for transplanta-
tion (P = 0.03 for both comparisons, Figure 8c).
Discussion
In this study, we demonstrated that circulating monocy-
tic EPCs were increased in the peripheral blood of SSc
patients. In addition, in vitro and in vivo functional ana-
lyses revealed that monocytic EPCs derived from SSc
patients had an enhanced ability to promote blood ves-
sel formation. This characteristic was primarily attribu-
table to an enhanced angiogenic property through
production of angiogenic factors. Additional studies to
identify monocytic EPC-derived soluble factors responsi-
ble for the difference in angiogenic property between
SSc patients and healthy individuals are underway. In
contrast, the EPCs’ ability to be incorporated into
vessels and differentiate into mature endothelial cells
was rather impaired in SSc patients. This finding may
support an early report showing that the angiogenic
capacity of PBMCs from SSc patients was inferior to
that of healthy controls, but when monocytes were
enriched and used in the same assay system, the SSc
patients’ samples showed an enhanced angiogenic capa-
city [21].
Monocytic EPCs promote angiogenesis by secreting a
variety of angiogenic factors, in a paracrine manner
[12,15,22,23], and by differentiating into other elements of
the vasculature, such as pericytes and smooth muscle
cells, thereby contributing to the outer layers of blood ves-
sels [11,12,24]. Skin biopsies from SSc patients were inves-
tigated for their angiogenic activity using the chick
embryo chorioallantoic membrane assay [25] and the
SCID mouse skin xenograft model [26], and in both
Figure 7 Capacity of monocytic EPCs to promote the formation of blood vessels in a tumor neovascularization model.
(a) Representative tumor sections stained with hematoxylin and eosin, from mice with transplants of CT-26 cells alone or of CT-26 cells and
monocytic EPCs from an SSc patient or a healthy control. Arrows indicate blood vessels carrying erythrocytes. Scale bars = 200 μm.
(b) Representative consecutive sections of the tumor stained with hematoxylin and eosin, from mice with transplants of CT-26 cells and
monocytic EPCs from an SSc patient. Asterisks indicate a relatively large blood vessel found in all consecutive sections. Dots indicate other blood
vessels carrying erythrocytes. Scale bars = 500 μm. (c) Vascular lumen density in tumors that arose from transplanted CT-26 cells alone or CT-26
cells with monocytic EPCs (10
4 or 10
5) from SSc patients or healthy controls.
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blood vessel formation in the surrounding normal tissue,
compared with grafts from healthy subjects. Since dense
mononuclear cell infiltrates were detectable around the
newly formed blood vessels in those models, it is likely
that SSc skin has a strong intrinsic activity that recruits
angiogenic cells, such as monocytic EPCs, from the circu-
lation, probably through chemokine production. Taken
together, the robust angiogenic push observed in SSc
patients may result, in part, from crosstalk between the
affected tissue and circulating monocytic EPCs. In addi-
tion, capacity of circulating monocytic EPCs in SSc
patients to home to the pathogenic site appears to be
intact.
One of the limitations of this study is the method
employed to quantify circulating monocytic EPCs, which
used the short-term culture, instead of a direct analysis
of freshly prepared cells. This is because of a lack of a
definitive marker for monocytic EPCs in circulation.
Our method is able to enrich monocytic EPCs from
PBMCs by utilizing the capacity of monocytic EPCs to
bind to fibronectin. Variability in the fibronectin binding
capacity may influence the recovery of monocytic EPCs
in the culture, but there was no difference in an
Figure 8 Incorporation of monocytic EPCs into vascular lumen in vivo in a tumor neovascularization model. (a) Representative tumor
sections stained for mouse CD31 (red) and human CD31 (green), from mice with transplants of CT-26 cells alone or of CT-26 cells and
monocytic EPCs from an SSc patient or a healthy control. Nuclei were counterstained with TO-PRO3 (blue). Arrows indicate blood vessels. Scale
bars = 200 μm. (b) Representative tumor sections stained for mouse CD31 (red) and human CD31 or HLA class I (green) from mice with
transplants of CT-26 cells and monocytic EPCs from a healthy control. Negative controls were sections incubated with isotype-matched mouse
or rat mAb to an irrelevant antigen, instead of the primary antibody. Nuclei were counterstained with TO-PRO3 (blue). Asterisks indicate blood
vessel lumen, while arrows indicate transplanted human monocytic EPCs located at the vascular wall. Scale bars = 50 μm. (c) The vasculogenic
potency of monocytic EPCs was assessed by determining the proportion of vascular lumens carrying human CD31
+ endothelial cells in tumors
arising from CT-26 cells co-transplanted with monocytic EPCs (10
4 or 10
5) from SSc patients or healthy controls.
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nectin, between circulating CD14
+ monocytes from SSc
patients and those from healthy individuals (data not
shown). It has also been shown that weak proliferation
of adherent CD14
+ monocytes occurs during the first 24
hours of the culture [13], and rate of proliferation was
similar between SSc patients and healthy controls.
Although SSc patients have high levels of circulating
monocytic EPCs with enhanced angiogenic potential,
blood vessel formation is apparently insufficient in these
patients [1]. This suggests the presence of mechanisms
that inhibit angiogenesis at SSc-affected sites. Postnatal
angiogenesis governed by endothelial cells requires a ser-
ies of events, including a response to angiogenic stimuli,
proliferation, the coordinated expression of proteolytic
enzymes, degeneration of the extracellular matrix, and
migration into the matrical space [27,28]. In this regard,
microvascular endothelial cells derived from the skin of
SSc patients show an overproduction of metalloprotei-
nase-12 and the resultant impairment of urokinase-type
plasminogen activator receptor signaling [29] as well as a
reduction in tissue kallikreins 9, 11, and 12, which are
powerful effectors of angiogenesis [30]. In addition, a
recent microarray analysis of microvascular endothelial
cells derived from the skin of SSc patients and controls
revealed the up-regulation of genes that suppress angio-
genesis and the down-regulation of genes critical to cell
migration and extracellular matrix-cytoskeleton coupling,
which impedes angiogenesis [31]. This anti-angiogenic
environment in SSc-affected tissue might interfere with
the pro-angiogenic property of monocytic EPCs. Given
the defective vasculogenic capacity of monocytic EPCs as
well as of “classic” EPCs [7], it seems that the final bal-
ance between blood vessel formation and repair favors
the suppression of neovascularization in SSc patients.
Monocytic EPCs are recruited into the circulation in
response to chemokines, such as monocyte chemoattrac-
tant protein-1 (MCP-1) [32], which are up-regulated in
the affected skin of SSc patients [33,34]. In addition,
endothelial cells are shown to strongly induce circulat-
ing monocytes to differentiate into EPCs under hypoxic
conditions [35], which is a typical feature of SSc skin
[36]. In contrast, Zhu et al. reported that SSc serum
induces the apoptosis of circulating EPCs through up-
regulation of the pro-apoptotic protein Bim, an effect
mediated by the inhibition of the activation/phosphory-
lation of Akt [37]. Therefore, in SSc patients, it is likely
that the signals that mobilize monocytic EPCs are so
intense that they overcome the mechanisms that reduce
the number of circulating monocytic EPCs. The pre-
sence of multiple confounding factors that affect the
number of circulating monocytic EPCs may explain why
their number did not correlate with any clinical charac-
teristics of the SSc patients.
In SSc patients, functionally altered monocytic EPCs
would be expected to accumulate at the affected tissue,
but it is unclear how they are involved in the pathogenesis
of SSc, given the strong anti-angiogenic microenvironment
in the affected tissue. We previously reported that mono-
cytic EPCs can differentiate not only into endothelial cells,
but also into a variety of mesenchymal-lineage cells,
including adipocytes, osteoblasts, chondrocytes, fibro-
blasts, and skeletal and cardiac myoblasts, when they are
exposed to lineage-specific induction stimuli [13,14]. Since
it has been reported that monocytes acquire the ability to
produce extracellular matrix components, such as col-
lagens, in the presence of MCP-1 [38], fibrogenic environ-
ment of the affected tissues in SSc patients may induce the
differentiation of monocytic EPCs into fibroblast-like cells.
Alternatively, monocytic EPCs recruited to the SSc-
affected sites could be a source of soluble factors, such as
MCP-1, platelet-derived growth factor, and interleukin-6,
all of which accelerate fibrosis.
Conclusions
In summary, despite insufficient vascular formation and
repair in SSc patients, monocytic EPCs are paradoxically
increased in the circulation and possess a prominent angio-
genic potential. These functionally altered monocytic EPCs
apparently cannot overcome the anti-angiogenic environment
at SSc-affected sites, and may eventually be involved in other
aspects of SSc pathogenesis, such as the promotion of exces-
sive fibrosis. Further studies investigating the role of monocy-
tic EPCs in the tissue fibrosis in SSc patients are underway.
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